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Abstract
Chronic myeloid leukemia (CML) is a cancer of the hematopoietic system and has been treated with the drug Imatinib
relatively successfully. Drug resistance, acquired by mutations, is an obstacle to success. Two additional drugs are now
considered and could be combined with Imatinib to prevent resistance, Dasatinib and Nilotinib. While most mutations
conferring resistance to one drug do not confer resistance to the other drugs, there is one mutation (T315I) that induces
resistance against all three drugs. Using computational methods, the combination of two drugs is found to increase the
probability of treatment success despite this cross-resistance. Combining more than two drugs, however, does not provide
further advantages. We also explore possible combination therapies using drugs currently under development. We
conclude that among the targeted drugs currently available for the treamtent of CML, only the two most effective ones
should be used in combination for the prevention of drug resistance.
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Introduction
Chronic myelogenous leukemia (CML) is a cancer of the
hematopoietic system and is initiated and driven by the product of
the BCR-ABL fusion gene [1–4]. It proceeds in three stages: the
chronic phase in which the number of cells is relatively low and the
degree of cellular differentiation is relatively high; the accelerated
phase during which the number of cells starts to rise to higher
levels and the degree of differentiation declines; and blast crisis,
which is characterized by explosive cell growth and a low degree of
differentiation. Small molecules that specifically target the BCR-
ABL gene product provide a successful treatment approach which
can lead to a reduction of BCR-ABL+ cells below detectable levels,
at least during the early stages of the disease. The drug Imatinib
has been mostly used in this respect [4–9]. As the disease advances,
however, the chances of treatment failure rise due to the presence
of drug resistant mutants that are generated mostly through point
mutations, but also through gene duplications [5,6,8–15]. Drug
resistance can potentially be overcome by the combination of
multiple drugs, where a mutation that confers resistance against
one drug does not confer resistance against any of the other drugs
in use. This is applied successfully in HIV infection [16].
Computational work has shown that a combination of three or
four different drugs against CML could similarly overcome the
resistance problem, even during advanced stages [17]. In addition
to Imatinib, the drugs Dasatinib and Nilotinib are alternative
inhibitors of the BCR-ABL gene product [18–21]. The reality,
however, is that one mutation (T315I) can confer resistance
against all those drugs [18–21]. We refer to this as cross resistance.
In addition to this one mutation, more than 50 mutations have
been identified that confer resistance against one of the drugs (in
particular imatinib), but not against the others [20,22]. Given this
situation, the question arises whether a combination of those three
drugs can improve treatment outcome. Here we examine this
question with a mathematical model.
Results and Discussion
We construct and analyze a mathematical model that is based
on a previously published computational framework [17]. This is a
stochastic, continuous time, birth-death process with mutations, by
which we describe the dynamics of a heterogeneous population of
cancer cells. The cells can divide, die, and mutate with given
probabilities. In particular, upon each division, a cell has a
probability to acquire resistance against a given drug by mutation.
Before the start of treatment, the colony undergoes a clonal
expansion until it reaches size N. At this time, therapy is started;
the drug(s) are assumed to increase the death rate of susceptible
cells. This could potentially lead to a significant reduction of BCR-
ABL+ cells in the absence of resistance. We calculate the
probability that drug resistant mutants will lead to treatment
failure, and the complementary probability of treatment success.
The model includes several biological parameters. The colony
size at start of treatment is assumed to vary within 10
8–10
13 cells.
The death rate of cells in the absence of treatment is between 0
and 70% of their birth rate. In the presence of drug therapy,
susceptible cells have an additional, drug-induced death rate which
can be one to ten times greater than the cells’ division rate. In the
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rate given by the maximum drug-induced rate in the combination.
We assume that there are of the order 10–100 different point
mutations that can confer resistance against only one of the drugs.
There is also one particular mutation which can confer resistance
against all drugs in use. Our general modeling approach continues
the tradition of Goldie and Coldman [23–25] in that we view a
cancerous colony as a stochastic birth-death process; the main
differences include the possibility to use drugs in combination rather
than sequentially; the existence of combinatorial mutation networks
and a non-zero cellular death rate. More mathematical details of the
model are provided in the supporting online Material S1.
First, consider the combination of two drugs. For reference,
Figure 1 shows the probability of treatment success for one and
two drugs assuming the absence of cross resistance. This is
compared to the cross-resistance scenario. While the probability of
treatment success is lower in the presence than in the absence of
cross resistance, combining two drugs with cross-resistance clearly
improves the probability of treatment success relative to the use of
only one drug. The reason is that it is much more likely to acquire
a mutation that confers resistance against only one drug than to
acquire the cross-resistance mutation. This is because only one
specific mutation can lead to cross-resistance, while many
mutations can confer resistance against only one drug. Hence,
for most mutations, combination therapy will not be challenged by
cross-resistance. On a qualitative level, this result does not depend
on the kinetic parameters of the model, such as the division and
death rates. The advantage of combining two drugs becomes
insignificant if the number of mutations that confer resistance to
only one drug is very low (Figure 2b), or if the rate at which the
cross-resistance mutation is acquired is relatively high. If the
number of mutations that confer resistance against only one drug
is on the order of 50–100, and if the rate at which resistance
mutations are generated is on the order of 10
26–10
29, however,
the model suggests that combining two drugs is advantageous to
the patient, even if cross-resistance is possible.
Next, consider the combination of three drugs, i.e. Imatinib,
Dasatinib and Nilotinib. The model shows that combining three
drugs will not lead to any further advantage compared to the
combination of two drugs (Figure 1). For triple combination
therapy to be advantageous, most resistant cells must harbor
mutations that render them resistant against two of the drugs (but
not the third one). Accumulating two separate resistance
mutations, however, is a relatively rare event. It is much more
likely that a cell acquires the single cross-resistance mutation.
Hence, triple combination therapy does not improve the
probability of treatment success compared to double combination
therapy. Triple combination therapy can only provide an
additional advantage if the number of mutations that confer
resistance against only one drug is unrealistically high (Figure 2b).
Assuming reasonable values for the cellular division, death, and
mutation rates, there must be at least k=1000 mutations that
confer resistance against only one drug for triple combination
therapy to somewhat improve the chances of treatment success.
The improvement becomes significant for k=10,000 or more
mutations (Figure 2b). For such high values of k we observe that
the effect of cross-resistance is insignificant and treatment failure
occurs as a result of mutations that confer resistance to one drug at
a time. In this case combining three (cross-resistant) drugs gives a
better outcome than two non-cross-resistant drugs (see figure 2b).
Again, these results do not qualitatively depend on the kinetic
parameters of the model. Figure 3 demonstrates how the
Figure 1. The probability of treatment success is plotted as a function of the colony size, N. Different curves correspond to different
combination treatments, with one, two and three drugs. The cross-resistance networks are presented by using connected and disconnected
nodes. The number of nodes corresponds to the number of drugs used. Connected nodes correspond to the existence of a cross-resistant mutation.
Identical connecting lines indicate that the same mutation confers cross-resistance to all connected drugs. Different (single, double, dashed) lines
correspond to different mutations. Simulation parameters are as follows: m=10
29, k=100, M0=100, d/l=0.5, h/l=3. The symbols ‘‘I’’, ‘‘D’’, ‘‘N’’, and ‘‘K’’
stand for ‘‘Imatinib’’, ‘‘Dasatinib’’, ‘‘Nilotinib’’ and a future drug which can bind to T315 mutants.
doi:10.1371/journal.pone.0004423.g001
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resistant drug therapies changes as a function of the natural cancer
cell death rate (a) and drug-induced death rate (b).
In summary, the analysis shows that in the context of the
currently available drugs for CML therapy (Imatinib, Dasatinib,
and Nilotinib), combining two of them can provide an advantage
over using one drug alone. Recent experimental data support this
notion [19]. However, combining all of these drugs does not
improve the chances of treatment success beyond double
combination therapy. Hence, the two most effective drugs should
be given simultaneously to treat CML.
While these results are robust and do not break down in the
context of biologically reasonable values of the cell death rates and
drug-induced death rates (figure 3), the largest degree of uncertainty
exists regarding the relationship between the number of tumor cells
and the probability of treatment success. As evident in Figure 1, the
probability of treatment success is only high if the number of tumor
cells upon start of therapy is no larger than 10
10. However, many
more tumor cells than this are found in patients when the disease
becomes detectable, and especially during more advanced stages.
On the other hand, the tumor cell population is heterogeneous, and
it is not clear to what extent different cell populations contribute to
the disease dynamics [26,27]. For example, if only the more
primitive tumor stem cells and progenitor cells are important
determinantsof tumorgrowth,thenthe effective population sizethat
our model refers to is significantly lower than the overall number of
tumor cells detected in a patient.
In general, we examined all possible resistance networks for
three-drug therapies. These networks are represented by circles in
Figures 1 & 2. They consist of nodes corresponding to different
drugs; each pair of circles is connected if there exists a mutation
event that confers cross-resistance against the two drugs. Different
lines (single, double, dashed) corespond to different mutations.
There are five possible three-drug cross-resistance networks,
including the absence of resistance and triple cross-resistance,
exemplified by the case of Imatinib, Dasatinib and Nilotinib. Here
we examine all intermediate possibilities. Let us suppose that there
is some cross-resistance between drug K and, say, I. In other
words, even though the T315I mutation does not confer resistance
to K, there may be a different mutation which makes the cell
resistant to both K and I, but not to D. In this situation, treating
with I and K is obviously better than just treating with I (this
follows from our previous results), but what is interesting, adding D
does give an advantage in this case. Adding D will even give an
advantage if there is a third mutation which confers resistance to
both K and D (but not I). In other words, even though treating
with three drugs characterized by triple cross-resistance does not
improve the chances of treatment success compared to two such
drugs, treating with three pairwise-cross-resistant drugs is advan-
tageous compared to treating with two such drugs.
General cross-resistance networks have relevance for future
generation treatment options. If drugs are used that show no cross
resistance with Imatinib, Dasatinib, and Nilotinib, such as VX-680
[22,28–33], would it be advantageous to combine such a drug with
two or more drugs that do not inhibit the T315I mutation? Our
calculations show that it is advantageous to combine such a future
Figure 2. The probability of treatment success is plotted as a
function of the colony size, N. (a) The number of non-cross-resistant
mutations is low (k=10) and the mutation rate for cross-resistance is 10
times higher than in figure 1. Conclusion: combining more than one
cross-resistant drugs does not improve the chances of treatment
success. (b) The number of non-cross-resistant mutations is high,
k=10
4. Conclusion: combining three cross-resistant drugs improves the
chances of treatment success compared with two cross-resistant or
non-cross-resistant drugs (which in turn is better than using only one
drug). The rest of parameters are as in figure 1.
doi:10.1371/journal.pone.0004423.g002
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the T315I mutation , say, Imatinib (I) and Dasatinib (D). This is seen
forexampleinfigure1whenwecomparetheprobabilityoftreatment
success for two cross-resistant drugs with that for ‘‘pairwise cross-
resistant’’ drugs. We observe that any of the pairwise cross-resistant
combinations of three drugs gives a significant improvement. Note
that adding a third cross-resistant drug does not improve the chances
of successful therapy. In future work, we will explore the possibility of
treatment combinations of currently used drugs, as well drugs under
development, based on in vitro data such as published in [19,34].
To conclude, we performed quantitative studies of drug cross-
resistance in CML treatment. The mathematical framework
created here is general enough to be applied to other cancers.
However, the model analyzed is specific to CML and the existing
drugs Imatinib, Nilotinib and Dasatinib. We predict that (i)
combining two cross-resistant drugs improves the chances of
treatment success, (ii) combining more than two drugs that do not
inhibit the T315I mutation does not increase the probability of
treatment success compared to combinations of two drugs, and (iii)
once a drug effective against T315I mutants becomes available,
the most effective treatment strategy is to combine that drug with
two of the three presently existing drugs.
Materials and Methods
Our work is based on mathematical analysis of stochastic
processes, describing the dynamics of drug sensitive and drug
resistant cell populations, both in the pre-treatment phase and
during therapy. Mathematical details are given in the supporting
online Material S1.
Supporting Information
Material S1 Supporting online material
Found at: doi:10.1371/journal.pone.0004423.s001 (0.08 MB
PDF)
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